SEL 212

Drug Profile

SEL 212

Alternative Names: Non-immunogenic uricase; Pegadricase-SVP; Pegsiticase-SVP; SEL-037/SEL-110; SEL-212; SVP-Rapamycin/pegsiticase

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Selecta Biosciences
  • Class Antigouts; Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout

Most Recent Events

  • 15 Jun 2017 Immunogenicity and adverse events data from a phase II trial in Gout presented at the Annual European Congress of Rheumatology (EULAR 2017) and Federation of Clinical Immunology Societies’ Annual Meeting (FOCIS 2017)
  • 27 Mar 2017 Selecta plans a phase III trial for Gout in USA in 2018
  • 27 Mar 2017 Efficacy and adverse event data from a phase II trial in Gout released by Selecta Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top